<DOC>
	<DOCNO>NCT00504777</DOCNO>
	<brief_summary>This single arm study assess safety efficacy MabThera combination methotrexate patient rheumatoid arthritis inadequate response intolerance one anti-TNF agent . Patients receive MabThera 1000mg i.v . day 1 15 , methotrexate ( 10-25mg/week p.o . parenteral ) , together methylprednisolone 100mg i.v . prior infusion MabThera . The anticipated time study treatment 3-12 month , target sample size &lt; 100 individual .</brief_summary>
	<brief_title>A Study MabThera ( Rituximab ) Combination With Methotrexate Patients With Rheumatoid Arthritis Who Have Had Inadequate Response Anti-TNF Agents .</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>adult patient , &gt; =18 year age ; active rheumatoid arthritis ; receive outpatient treatment ; inadequate response , intolerance , &gt; =1 antiTNF agent . rheumatic autoimmune disease inflammatory joint disease ; concurrent treatment antiTNFalpha therapy ; joint osseous surgery 8 week prior recruitment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>